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Introduction
The history of the association between oral contraceptive
(OC) use and venous thromboembolism (VT) began more
than 35 years ago. Doctor Jordan, a general practitioner,
reported on a 40-year-old woman who developed pulmonary
embolism 10 days after stopping her mestranol and norethy-
nodrel medication for endometriosis. He concluded the
case-history in The Lancet (1) with the advice, "Because
enavid may produce uncontrollable vomiting and provoke
pulmonary embolism and infarction, I would counsel
caution in the use of this widely advertised drug." Since
then we are struggling with the association. Specialists and
committees were reluctant to accept a relationship on the
basis of case reports, until the more compelling report on
the association between OC use and VTE was published by
the Royal College of General Practitioners in 1967 (2). The
major frustration during the last 35 years, however, has
been lack of knowledge on how OC actually causes VTE,
despite studies to elucidate its mechanism.
In this chapter we discuss epidemiological data gathered
during 35 years of history, the search for patho-
physiological understanding, with emphasize on recently
found genetic and epidemiological data and we examine the
clinical relevance and implications of these data.
Epidemiology
1967-1995
In order to estimate the risk of first venous thrombosis for
women who used OCs äs a method of birth control, a
search for controlled trials published in English, French or
German from 1960 to 1993 in which an index group was
compared with a control group was conducted. The studies
were identified by using Medline and by exploring
references and reviews on this topic. A total of 588 articles
or abstracts were reviewed (3), of which only 15 (2.6%)
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were included in our examinations. These comprised one
randomized controlled trial (4), 6 follow-up studies (5-10)
and 8 case-control studies (2,11-17). The summary relative
risk of first thrombosis during oral contraceptive use was
2.9 with a 95% confidence interval from 0.5 to 17.
Validity ofthe Studies
The 15 studies proved to be highly heterogeneous with
regard to size and direction of the risk estimate (Fig. 1).
Interpretation of the studies äs a whole was therefore
difficult. In these studies, objective diagnostic methods such
äs venography, ultrasound, impedance plethysmography,
ventilation-perfusion scans, and postmortem examinations
were either not explored at all or were only performed in
some patients. The diagnostic problem could have led to
numerous false-positive diagnosis, resulting in an
overestimation of the RR. However, the more certain the
diagnosis (10-12,18,19) or the more severe the VT events,
the larger are the estimated relative risks. Thence,
Katerndahl et al. (20) in their meta-analysis found that the
method of diagnosis was not significantly related to RR.
Publication bias, caused by under-reporting smaller
studies with no significant effect äs a possible explanation
of the outcome is less plausible, has seen the relative
presence of smaller studies without a significant effect äs
depicted in Fig l.
Five studies reported on the use of oral contraceptives
containing 50 /ig or more of ethinyl-estradiol (EE2), and
four on doses less than 50 ^ g. In the remaining studies the
dosage was not stated at all. Various case-control studies
and cohort studies attribute the increased risk of VTE in OC
users to the estrogen content of the OCs, but this effect has
not consistently been shown to be related to dose (21,22).
The pooled summary estimate of case-control studies
(RR4.2) was higher than the pooled summary estimate of
the cohort studies (RR2.1). Cohort studies are considered
methodologically stronger than case control studies because
case-control studies can be affected by recall bias: a relative
over-reporting of pill use is more likely when the patient
suffered VTE äs controls are likely to underreport pill use.
Nevertheless, data from Glass et al. (23) and Stolley et al.
(24) indicate that current or recent OC use is reported
accurately. Interestingly, the only RCT, a study design least
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Fig. 7 Funnel plot of the relative risks and 95% confidence
intervals ranked by Standard error. FUP denotes follow-up study,
CC case-control study and RCT randomized controlled trial.
(A) represents the pooled unweighted relative risk; (B) represents
the classical precision weighted (usmg mverse variance weights)
pooled relative risk [from (3)].
likely to be biased, showed no difference in risk of VTE
between 4965 OC users and 4933 vaginal barrier users (4).
Although every study is likely to be affected by at least
some bias, nearly all have reported elevated risk estimates
of VTE after OC, increasing the plausibility of a causal
relationship between current OC use and VT. Finally, it is
characteristic of trae association that this shows up whatever
the shortcomings of studies set up to investigate it (albeit
that an important flaw common to all studies can still
produce erroneous conclusions.)
Smoking does not appear to be a risk factor for VTE
(6,12,14,15,25); obesity (12,19) and varicose veins (6) are
at most weak risk factors. Risk of VTE in pill users is
unrelated to duration of OC use (11,12,18), and none of the
studies have demonstrated an increased risk of VTE among
past users or once the pill use has been stopped.
Recent Studies and Absolute Numbers
In recent studies in which the sub-50 (/ig EE2 containing)
puls were investigated comparing current users with non-
users, the relative risk (RR) is 2.1 for fatal VT and pulmo-
nary embolism (PE) (26), 3.8 for non-fatal deep venous
thrombosis (DVT) (27), and 2.7 for superficial VT, DVT
and PE (28). The data indicate that OCs containing less than
50 μg EE2 may still carry a risk of VTE. As the baseline
incidence of deep VTE among young women who do not
use OC is between 0.5-1 per 10,000 year (29-31), we can
expect 20-40 cases annually with non fatal DVT per
100,000'women using sub-50 OCs [about one million
women in the Netherlands use OCs throughout the year (32)
and 10-20 cases with fatal VT and PE]. Case fatality of
VTE is between 1-2% in young persons (33). The
recurrence risk of VTE is not well known, especially among
OC users. This is particularly remarkable since concern
about recurrent venous thrombosis led many physicians to
advise women to cease use of OCs after a first thrombotic
episode (34). Our attempt at quantifying the difficult clinical
decision whether or not to discontinue oral contraceptives
after a first thrombosis has led to the startling result that we
lack the necessary data to answer this question (3). Only
follow-up study on recurrence risk will settle the issue.
Coagulation
As a plausible mechanism behind the increased risk of VTE
in OC users, it was suggested that in OC users activation of
coagulation and fibrinolytic Systems could alter the delicate
dynamic hemostatic balance so that VTE can develop
(35,36). Many studies indeed show changes in the activation
of coagulation and fibrinolytic compartments, albeit within
the normal ränge. Pathological estimates could not be found
or may have escaped detection because the investigated
persons were few, were healthy volunteers, and in a static
hemostatic Situation when the blood samples were taken.
Moreover, investigators in general were more con-cerned
with VTE factors than are risk factors for arterial disease,
such äs smoking and hypertension, and with measuring all
kind of biochemical and hematology variables for safety
reasons, required by the authorities than in true clinical
outcomes. During at least the last decade the gold Standard
for examining the thrombogenic potential of (newly
introduced) OC preparations is and was measuring the
variables in the hemostatic System in young healthy
volunteers. Epidemiology had to show us that clinical
endpoints were of more relevance.
Inheritable Clotting Defects
A major leap ahead in the understanding of the clotting
mechanism in OC users arose from an epidemiological
study on an interaction between a newly discovered
inheritable coagulation disorder and OC use (27). Factor V
Leiden, a single point mutation in the Factor V (37) leading
to the resistance to activated protein C, was studied in a
population-based case-control study, the Leiden Thrombo-
philia Study (LETS) (38).
In the Leiden study, 474 consecutive patients with
objectively confirmed first DVT occurring between 1988
and 1993 were recruited from three anticoagulation clinics
which monitor all anticoagulant treatment in a well-defmed
geographical area. A healthy control subject of the same sex
and approximately same age was drawn for each patient.
Six to 19 months after the acute event, all patients and
control subjects were thoroughly interviewed, and blood
samples were taken. For the analysis of OC users, 155
patients and 169 controls aged between 15 and 49 years,
who were premenopausal, non-pregnant and not in their
puerperium, were included.
The carrying of Factor V Leiden (FVL) increases the
risk of DVT almost eight-fold, use of oral contraceptives
increases the risk four-fold; and in combination they should
increase the risk to a maximum of 30-fold. However, the
actual risk of DVT in OC using carriers of FVL was 35,
which is higher than the summed effect of both factors. This
implies that the simultaneous presence of both risk factors
leads to an additional number of women experien-cing
thrombosis than would have been expected if the risks were
independent. Thence, the two factors showed a
328
The PiU and VTE
Tobte l Absolute risk of deep venous thromboembolism
FVL OCuse Incidence per 100,000 wotnen (years)
8
30
57
285
Table 2 Prevalence of heritable clotting defects in a healthy
population and among VTE patients
Antithrombin
Protein C
Protein S
FVL
Healthy
population
0.2
0.2
1.3
Caucasian,
3-5%
VTE
patients
1.1
2.7
1.3
20% of consecutive,
random VTE patients;
50% of unexplained
VTE
Ref.
38,39
38,40
38
38
synergistic effect. This means that in the presence of both
factors, thrombosis will occur in a substantial number of
women who would not have experienced thrombosis if they
have only one of the risk factors.
The biological background might be that FVL and oral
contraceptive use both lead to changes in the anticlotting
cascade, for instance the activation of protein S and C,
which enhance each other. Since FVL and OC use are
common risk factors, this synergistic effect may affect many
women. The incidence calculated from the LETS data are
shown in Table l, while prevalence data on the known
inheritable clotting factors are shown in Table 2. The
absolute risk of D VT for antithrombin, protein C, protein
S deficiency in non OC and OC users are low (41).
Screening
The finding of a genetical cause for a disease is nearly
always accompanied by a strong desire to screen for the
trait. Screening recommendations for FVL in potential OC
users were no exception. Such policy, however, might deny
effective contraception to about 5% of white women, while
preventing only a small number of deaths due to PE. Taking
a personal and family history of DVT when prescribing OC
will detect persons from families with a tendency to
multiple VTE and might be worthwhile (42). A genetic
defect in the coagulation System, such äs factor V Leiden,
is not an absolute contraindication for pill use, but should
always be subjected to assessment of individual risk (43).
Third-Generation Progestins
Representatives of first-generation progestins, derivatives of
nortestosterone, are norethisterone and lynestrenol. At the
end of the 1960s the second-generation progestin,
levonorgestrel (LNG), which is also a derivative of
nortestosterone, was introduced. The third-generation
progestins, derivatives of LNG, were developed to reduce
androgenic metabolic side-effects with a similar or even
higher contraceptive efficacy. Representatives of this group
are desogestrel (DSG) and gestodene (GSD). A third
derivative, norgestimate (NGM), is difficult to classify
because it is partially metabolized to LNG and partially to
other intermediates.
Historically, the first-generation progestins were coupled
to high doses of estrogens, that is 50 /tg or more, Second-
generation progestins have been coupled to lower doses of
EE2, that is 30/tg in the monophasic pill, and were already
called lower dose pills. The third-generation gestagens
DSG, GSD and NGM contain also 30/tg EE2 or lower. In
Europe the major brands contain DSG and GSD, in the
USA NGM and in part DSG.
Four Studies: WHO
Most studies on VTE in OC users were undertaken in
northern Europe and in the US in the 1960s and 1970s
when higher doses of steroids were applied than today and
when objective diagnosis of VTE was lacking. WHO,
therefore, conducted an international multicentre, hospital-
based, case-control study between 1989-1993 (44). Included
were 1143 women (aged 22-44 years) with a history of
idiopathic VTE and 2998 age-matched controls. OC use was
associated with an increased risk of VTE both in Europe
(RR4.15; 95%CI 3.09-5.57) and in non-European
countries (RR3.25; 95%CI 2.59-4.08). These figures were
unaffected by certainty of diagnosis (definite, probable,
possible), the age of the user, a history of hypertension or
by smoking, the last two being risk factors for arterial
disease. A body mass index of more than 25 kg/m2 was an
independent weak risk factor for VTE, predominantly
among users of DSG and GSD containing pills. Totally
unexpected, the WHO study showed a further doubling or
tripling of the risk of VTE among users of third-generation
OCs. In a detailed analysis (29) comparing 769 cases with
1979 age-matched hospital controls and in one centre with
246 community controls matched for age and general
practice, there was a three-fold elevated risk of VTE in
women using LNG and a 9-fold risk in women using DSG
or GSD containing pills compared with non-users. A direct
comparison of DSG and GSD containmg pills with LNG-
OCs revealed risk estimates of 2.2 and 3.0, respectively
(adjusted for body mass index).
Four Studies: GPRD
The scientists from WHO needed a second opinion and
asked Professor Jick from Boston for an analysis of the
database of the General Practice Research Database
(GPRD), owned by the UK Health Departments, com-
prising 238,130 women (30). The RR of VTE associated
with DSG and GSD containing OCs was twice that of LNG
pills. The excess risk for VTE among women using DSG
and GSD containing OCs compared with those containing
LNG was 16 per 100,000 women years (Table 3).
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Tabk 3 Absolute risk of non-fatal VTE (30)
Group Non-fatal VTE cases per 100 women (years)
Table 4 RR of VTE among women aged 25-44 years who used
different OCs [see (46) by year of market introduction]
non-OC users
OC with LNG
OC with DSG
OC with GSD
3 8
16.1
29.3
28.3
Four Studies: LETS
From the original LETS data base (38), 126 women and
159 controls were selected with the following criteria:
known type of pill used at the time of thrombosis (index
data were obtained from an interview and checked with the
hospital discharge letter), complete information available on
the pill type, and that at least five cases and controls per
type of pill were used. A positive family history was
defined äs one or more parents or siblings with VTE. The
highest age-adjusted RR was found for the DSG containing
pill of 8.7. All other OC types, including puls containing a
second-generation progestin and 50jug EE2, gave a risk
ranging from 2.2 to 3.8. The RR for the DSG containing
pill was similar among women with and without a family
history, which means that preferential prescription because
of family history cannot explain these Undings. Nor could
the excess risk be explained by previous pregnancy, and the
risk was highest in the youngest age categones where one
would expect most new users (31).
Four Studies: Transnational
At the request of, but not funded by, the German
authorities, the Transnational case-control study was under-
taken in response to concern that GSD might increase the
risk of vascular events. In an interim report (45) on 471
cases and 1772 controls, the adjusted odds ratio for VTE in
OC-users vs. non-users was 4 (95% CI 3.1-5.3); the odds
ratio for DSG and GSD containing OCs vs. second-
generation products was 1.5 (95% CI 1.1-2.1).
Biases
The publication of these four Studies prompted a series of
similar counter-arguments in letters to publishers and again
in recent publications. Attention was drawn to biases such
äs starter/healthy user bias, prescribing bias, referral bias
and diagnostic bias.
Starter and healthy user bias means that venous
thrombosis occurs mainly at the Start of OC use and that the
Starters generally had the new, third-generation OCs. Thus,
among these first-time users, the women who are most at
risk, are susceptible to the thrombogenic effects of OCs, use
the new third-generation puls. In contrast, second-
generation pill users in the studies consist mainly of healthy
women who had already used the pill for a long time and
who had never developed thrombosis, not even during
pregnancy, and therefore stayed with their trusted brand. In
short: the second-generation products users are a selection
of healthy users, the third-generation users are susceptible
for thrombosis.
OC Year of market introduction RR of VTE
LNG
POP
DSG+30^g EE2
GSD
NGM
DSG+20itgEE2
1972/74
1971/74
1981
1986
1986/92
1992
1
1.1
1.5
2
2.4
2.8
Tabk 5 RR of VTE among women aged 16-24 years and 25-44
years (derived from Table 4) who used different OCs
OC RR of VTE in women (years)
16-24 25-44
LNG
POP
DSG+30^gEE2
GSD
NGM
DSG+20jigEE2
1
1.9
2.6
1.4
1.7
0.4
1
1.1
1.5
2
2.4
2.8
This, in principle, is a worthwhile argument. The authors
of the Transnational tried to Support the healthy user effect
by their fmding that a successive increase of VTE risk
among women aged 25-44 years was associated with the
introduction of a new OC on the market, in comparison
with LNG (46) (Table 4).
Reconstructing the data of the women aged 16-24 years,
which comprise one-third of the cases and nearly 50% of
the controls, we arrive at the data, shown in Table 5,
indicating an overall higher VTE risk of third-generation
products and almost an inverse relation with the year of OC
introduction, which refutes the conclusion of the authors of
the Transnational study (46).
Another argument that mitigates against this type of bias
is that the difference in RR for VTE 1?etween third- and
second-generation OCs did not disappear when the group of
first-time users, who experienced VTE for the first time,
was excluded (Table 6). All four studies actually dealt with
first thrombosis events; in three of them the first-time users
were explicitly described. The RR in the group of the first-
time-users became slightly larger compared with the overall
figures.
VTE occurs frequently in the first year of OC use,
especially in first-time users. However, VTE among first-
time-users is twice äs frequently found in the group of third-
generation OC users group, äs in the second- generation OC
users group (29).
There is thus no justification to explain the effect by
starter/healthy-user bias.
Prescription bias means that third-generation products
were preferentially prescribed to women at high risk so that
the increased relative risk merely reflect a higher baseline
risk. When examining this argument, we should ask
ourselves how a prescribing physician would predict that a
young woman who has never had a venous thrombosis, is
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Table 6 RR of VTE concerning third-· vs second-generation OCs
RR
First-time user Later Overall
Transnational (45)
GPRD:
DSG (30)
GSD
WHO (29)
2.7
9.2
5.6
5.4
1.4
1.8
1.8
2.4
1.5
1.9
1.8
2.2-3
at higher risk of developing VTE, so that he or she would
prescribe a third-generation contraceptive. Smoking is not
a risk factor for VTE but is for arterial disease. Obesity is
not a risk factor; only gross obesity might be a weak risk
factor. Superficial varicose veins äs a result of an earlier
thrombotic event can be a weak risk factor, but all four
studies were restricted to first thrombosis events. The most
interesting risk factor for VTE is family history, in
particular when coupled to FVL. Yet, knowledge about
FVL is too recent to have influence of the results of the
four original studies.
A third objection is that all studies might have
overestimated the risk of OCs because of a diagnostic bias
towards a diagnosis of VTE in women who use the pill. In
the WHO (29) and the GPRD study (30), a separate
analysis was made for cases with definite and probable
diagnosis to see whether the association would disappear in
the more secure diagnosis. This was not the case.
Further, other potential biases have been put forwarded.
One argues that the newer studies have shown only a lower
frequency of thrombosis among second-generation users
compared to the earlier studies (47), which suggests that the
higher risk among third-generation users is not higher, but
equal to, second-generation users. The best comparisons
always remain those within studies than among studies
because the same diagnostic criteria were used, äs was the
case hl the four original studies.
With switching bias, one tries to indicate that headaches
and dizziness are reasons for switching from second- to
third-generation pills (48). There are no data to suggest that
these Symptoms are risk factors for VTE. Further, in some
databases one sees a switching in the direction of third-
generation pills, but in other databases the switch is the
other way around (49).
Mortality Rate
Protection against myocardial infarction (MI) by third-
generation vs. second-generation products was suggested by
one study> and in view of the wide confidence intervals this
has been overemphasized (50). While that finding has not
been confirmed by preliminary data from a Danish study
(51), one should also bear in mind that among women aged
15-49 years the mortality risk from VTE is higher than that
risk from MI (52).
Lidegaard and Milgrom (53) argued that an increase in
the overall incidence of VTE since the uitroduction of third-
generation pills should be expected but has not been demon-
strated, can be rebutted by the finding of a recent increase
in VTE mortality among young women both in the
Netherlands and in the United Kingdom (52,54).
Conclusion
Apart from the social and financial consequences, deep
venous thromboembolism may be followed by the serious
condition of pulmonary embolism and by post-thrombotic
syndrome. Despite adequate treatment, approximately 5%
of patients with DVT treated with heparin have major
bleeding. About 50% of patients with proximal vein
thrombosis and one-third of patients with DVT will suffer
from post-thrombotic syndrome, which is a chronic
complication with Symptoms of pain, swelling and
occasionally ulceration of the skin of the limb (55). Vessel
reflux, obstruction or both are observed in almost all
patients with the syndrome (56).
Before each treatment a physician must balance the pros
and cons based on a patient's history and the evidence
available. That policy should also apply tor the prescription
of oral contraceptives. A personal or family history of VTE
is reason for selective screening of inheritable coagulation
factors such äs the mutated factor V. Women with risk
factors should not be bluntly barred from OCs but should
always be subject to assessment of individual risk and
benefit. The first choice of prescription for healthy, first-
time users is a second-generation OC.
Drug regulatory authorities should be aware that
intermediate end-points have thus so far failed to adequately
address the thrombogenic potential of OC preparations (57)
and should adapt their operative regulations in asking for
more up-to-date assay protocols when dealing with such
products. The scientific Community is assiduously engaged
in elucidating which mechanism oral contraceptives inter-
fere in the development of venous thromboembolism.
Epidemiologists can concentrate, among others, on the
relative risk for thrombosis for each OC product and on the
likelihood of recurrence of VTE (58).
In combination such efforts can increase the safety of one
of the safest and most widely used categories of drugs: oral
contraceptives.
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Summary
Studies conducted in the first three decades after discovery
of a link between venous thromboembolism and oral
contraceptive users showed a relative risk of first throm-
bosis during oral contraceptive use of 2.9 (95% CI 0.5-17).
In recent studies in which the sub-50/ig ethinyl estrodiol
containing pills were investigated comparing current users
with non-users, the RR is 3.8 for non-fatal deep VTE and
2.7 for superficial VTE, deep VTE and pulmonary
embolism (PE) together and 2.1 for fatal VT and PE
together. The association is attributed to the estrogenic
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component and not related to duration of pill use. The risk
disappears once the pill has been stopped, and it is not
elevated among past users. Smoking does not appear to be
risk factor for VTE; obesity and varicose veins are, at the
most, weak risk factors.
Since a causal relationship between OC use and VTE is
tempting, clues for unraveling the mechanism were sought
in the hemostatic System. Studies of the coagulation system
found changes in the activation of coagulation and fibrino-
lytic compartments, but within the normal ränge. An
epidemiologic study showed that the risk of VTE among
women using OCs is 30-fold increased by the presence of
a mutation of factor V, called Factor V Leiden (5%
prevalence in the Caucasian population). Selective screening
for the mutated factor V should be limited to women with
a personal or family history of VTE.
Four epidemiologic studies showed a two-fold increase in
risk of VTE with the use of OCs containing third-
generation progestins (gestodene and desogestrel), relative
to second-generations products (levonorgestrel). Biases
cannot devaluate the conclusion that the increased risk of
VTE in especially first-time and younger users of third-
generation OCs is highly likely. The clinical consequence is
therefore that second-generation OCs are the first choice in
prescription to first-time users.
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